Personalized neoantigen vaccines turn mutations from an individual patient’s tumor into a custom immunotherapy, requiring sequencing, computational prediction and manufacturing to occur within the treatment window.
Targeted protein degraders do not simply occupy a disease protein and block its activity. They recruit the cell’s disposal machinery to remove it, potentially opening targets conventional drugs cannot reach.
FDA-cleared OTC glucose sensors have opened continuous monitoring to people who do not use insulin, but evidence for weight loss and broad metabolic improvement in people without diabetes remains limited.
Circulating tumor DNA can detect molecular traces of residual cancer after apparently curative treatment, but proving that acting on an earlier signal improves survival is the harder challenge.
Oral semaglutide demonstrated that a peptide can become a successful tablet, but extremely low and variable gastrointestinal absorption still makes most peptides poor candidates for oral delivery.
Radiotheranostics pairs molecular imaging with targeted radioactive drugs, allowing clinicians to confirm whether a tumor carries the therapeutic target before delivering radiation systemically.
Antibody-drug conjugates combine targeting antibodies with powerful cytotoxic payloads, but clinical performance increasingly depends on linker chemistry, drug-to-antibody ratio, payload properties and how the medicine behaves inside heterogeneous tumors.
Wearable devices are moving beyond step counts and wellness tracking to become clinical-trial instruments, but regulatory acceptance will depend on whether sponsors can prove that digital endpoints are accurate, meaningful and reliable across diverse patient populations.
Eli Lilly and Company has created a limited expanded-access pathway for adults with severe, treatment-resistant obesity, even as regulators warn that products sold online as retatrutide are unapproved, potentially contaminated and illegal to compound.
Alzheimer’s blood tests are moving from specialist research into clinical practice after real-world evidence showed that biomarker results sharply improved diagnostic accuracy. The opportunity is substantial, but differences between assays, inappropriate screening and laboratory-quality failures could undermine confidence.